Global Vaccine Market Outlook (2007-2010)

"Global Vaccine Market Outlook (2007-2010)" is an extensive market research report by RNCOS that gives an objective analysis on the global vaccine market. It covers both past and current performance of the market, as well as highlights the trends that are expected to impact the future of the market.

The global vaccine market, which was earlier thought as a low margin, low growth industry, is currently attracting the interest of all major pharmaceutical giants. The market is presently witnessing growth rates much faster than the traditional pharmaceutical market; and with many new blockbuster potential vaccines likely to hit the market in future, the growth is only expected to increase.

The biggest factor driving the vaccine market is its potential to prevent deaths due to diseases. Vaccines have eradicated many life-threatening diseases and many more vaccines are in the pipeline, which may serve as future life saviors (particularly those for several types of cancers which are expected to be launched around 2008). However, several challenges still remain, one of the biggest being the wide gap between the developed and the developing world in terms of accessibility and quality of vaccines.

Key Findings

• Growing at the rate of 16.52%, global vaccine market is expected to reach US$ 21.05 Billion by 2010.
• Cancer and addiction vaccines will grow rapidly through 2010.
• At present, pediatric vaccines occupy a higher market share but in future, this segment will loose its share to the adult, therapeutic and influenza vaccine segments.
• The US is the largest market globally for vaccines followed by Europe.
• Flu vaccines have huge demand at present and all major vaccine manufacturers are investing in the segment.
• Vaccines have been found to be more profitable than the generic pharmaceutical drugs but fetch fewer margins than branded drugs.
• The global vaccine market, in its bid to reduce costs and time to market, is likely to drive the global drug discovery CRO market.

Key Issues Analyzed

• Evaluation of past, current and future market trends.
• Discussion on major vaccines and their markets.
• Future forecast of major vaccines.
• Analysis of various challenges and opportunities for the industry.
• Categories of players operating in the market along with their business profiles.

Research Methodology Used

Information has been sourced from various credible sources like books, newspapers, trade journals and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

The analysis methods ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

• 1. Analyst View
• 2. Research Overview
• 3. Vaccines - An Introduction
  • 3.1 History
  • 3.2 Vaccine Production Stages
    • 3.2.1 Cultivation
    • 3.2.2 Purification
    • 3.2.3 Quality Control
    • 3.2.4 Packaging
  • 3.3 Vaccine Approval Process
    • 3.3.1 Phase I
    • 3.3.2 Phase II
    • 3.3.3 Phase III
    • 3.3.4 Phase IV
  • 3.4 Regulatory Frameworks & Intellectual Property Rights
    • 3.4.1 Product Equals Process
    • 3.4.2 Regulatory Requirements
    • 3.4.3 Patent Protections
  • 3.5 Types of Vaccine
    • 3.5.1 Live Attenuated Vaccines
    • 3.5.2 Killed Vaccines
    • 3.5.3 Toxoid Vaccines
    • 3.5.4 Component Vaccines
    • 3.5.5 Genetically Engineered Vaccines
    • 3.5.6 DNA Vaccines
• 4. Market Analysis
  • 4.1 Global Vaccine Market
• 5. Industry Performance
  • 5.1 Key Geographical Markets
    • 5.1.1 US
    • 5.1.2 Europe
    • 5.1.3 Japan
    • 5.1.4 China
    • 5.1.5 India
    • 5.1.6 Brazil
  • 5.2 Major Vaccine Segments
    • 5.2.1 Basic Pediatrics
    • 5.2.2 Enhanced Pediatrics
    • 5.2.3 Proprietary Pediatrics
    • 5.2.4 Adult/Travel
    • 5.2.5 Therapeutics
      • 5.2.5.1 Cancer Vaccines
      • 5.2.5.2 Addiction Vaccines
    • 5.2.6 Influenza
• 6. Major Pediatric Vaccines
  • 6.1 Pneumococcal Vaccines
  • 6.2 Polio Vaccines
  • 6.3 Varicella Vaccines
  • 6.4 Meningitis Vaccines
  • 6.5 Rotavirus Vaccines
  • 6.6 DTP Vaccines
  • 6.7 Measles, Mumps & Rubella (MMR) Vaccines
  • 6.8 Tuberculosis Vaccines
• 7. Major Adult/Travel & Therapeutic Vaccines
  • 7.1 Hepatitis B Vaccines
  • 7.2 Malaria Vaccines
  • 7.3 Japanese Encephalitis Vaccines
  • 7.4 Ebola Vaccines
  • 7.5 Cervical Cancer Vaccines
  • 7.6 Typhoid Vaccines
  • 7.7 West Nile Vaccines
  • 7.8 HIV Vaccines
• 8. Industry Analysis
  • 8.1 Market Drivers
    • 8.1.1 Diseases Prevention
    • 8.1.2 Higher Margins
    • 8.1.3 Increased Funding from Government & NGOs
    • 8.1.4 Government Regulations
    • 8.1.5 Blockbuster Potential of New Vaccines
    • 8.1.6 Increasing Population in Developing Countries
    • 8.1.7 Disease Awareness
  • 8.2 Opportunities
    • 8.2.1 Contract Research
    • 8.2.2 Influenza Vaccine Segment
    • 8.2.3 India & China - Future Hub for Pediatric Vaccine Manufacturing
    • 8.2.4 Cancer Vaccine Segment
    • 8.2.5 Addiction Vaccine Segment
  • 8.3 Challenges
    • 8.3.1 Huge R&D Cost
    • 8.3.2 Lack of Infrastructure for Trials & Manufactures
    • 8.3.3 Effective Vaccine Design
    • 8.3.4 Vaccine Supply
    • 8.3.5 Immunization Safety
• 9. Vaccine Market Players
  • 9.1 Major Categories
    • 9.1.1 Vaccine Majors
    • 9.1.2 Vaccine-focused Biotech Companies
    • 9.1.3 Domestic-focused Vaccine Companies
  • 9.2 Key Players
    • 9.2.1 Sanofi-Aventis
    • 9.2.2 GlaxoSmithKline Plc.
    • 9.2.3 Merck & Co., Inc.
    • 9.2.4 Novartis
    • 9.2.5 Wyeth
• List of Figures:
  • Figure 3-1: Vaccines Horizon* (1960 to 2010)
  • Figure 4-1: Global - Vaccine Market (in Billion US$), 2003-2006E
  • Figure 4-2: Global - Forecast for Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-1: Global - Vaccine Market Segmentation by Region (%), 2005
  • Figure 5-2: Global - Sales Split of Major Vaccine Player by Region (%), 2004
  • Figure 5-3: US - Vaccine Market (in Billion US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-4: US - Pediatric Vaccine Market (in Billion US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-5: US - Hepatitis Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-6: US - Biodefense Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-7: US - Influenza Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-8: US - Travel Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
  • Figure 5-9: US - Developmental Vaccine Market (in Million US$), 2008E & 2013E
  • Figure 5-10: Europe - Vaccine Market (in Billion US$), 2005, 2006E, 2008E & 2012E
  • Figure 5-11: Japan - Influenza Vaccine Production (in Million Units), 2004-05, 2005-06 & 2006-07E
  • Figure 5-12: China - Vaccine Market (in Billion RMB) 2004-2006E
  • Figure 5-13: China - Forecast for Vaccine Market (in Billion RMB) 2007-2010
  • Figure 5-14: India - Vaccine Market (in Million US$) 2004-05 to 2008-09E
  • Figure 5-15: India - Share of Domestic Consumption & Exports in Vaccine Market (%), 2005-06
  • Figure 5-16: India - Share of Public & Private Sectors in Vaccine Market (%), Nov 2006
  • Figure 5-17: India - Top 6 Selling Drugs in Vaccine Market (in Rs Crore), 2005-06
  • Figure 5-18: Brazil - Vaccine Market (in Million BRL), 2000, 2004, 2006E & 2008E
  • Figure 5-19: Brazil - Share of Public & Private Sectors in Vaccine Market (%), 2000
  • Figure 5-20: Global - Vaccine Market by Segment (in Billion US$), 2005, 2006E & 2010E
  • Figure 5-21: Global - Share of Vaccine Market by Segment (%), 2005, 2006E & 2010E
  • Figure 5-22: Global - Basic Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-23: Global - Forecast for Basic Pediatrics Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-24: Global - Enhanced Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-25: Global - Forecast for Enhanced Pediatrics Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-26: Global - Proprietary Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-27: Global - Forecast for Proprietary Pediatrics Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-28: Global - Adult/Travel Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-29: Global - Forecast for Adult/Travel Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-30: Global - Therapeutics Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-31: Global - Forecast for Therapeutics Vaccine Market (in Billion US$), 2007-2010
  • Figure 5-32: Global - Cancer Vaccine Market (in Billion US$), 2005, 2008E & 2010E
  • Figure 5-33: Global - Addiction Vaccine Market (in Million US$), 2008E & 2010E
  • Figure 5-34: Global - Influenza Vaccine Market (in Billion US$), 2005 & 2006E
  • Figure 5-35: Global - Share of Influenza Vaccine Production by Manufacturer (%), 2006
  • Figure 5-36: Global - Forecast for Influenza Vaccine Market (in Billion US$), 2007-2010
  • Figure 6-1: Global - Pneumococcal Vaccine Market (in Billion US$), 2006 & 2010E
  • Figure 6-2: Global - Number of Polio Incidences (2004-2006)
  • Figure 6-3: Global - Countries with Maximum Number of Polio Incidences, 2006
  • Figure 6-4: Global - Polio Vaccine Market (in Million US$), 2004 & 2011E
  • Figure 6-5: Global - Inactivated Polio Vaccine Doses (in Million), 2006 & 2011F
  • Figure 6-6: Global - Meningitis Vaccine Market (in Billion US$), 2004 & 2010E
  • Figure 6-7: Global - Forecast for Rotavirus Vaccine Market (in Billion US$), 2010
  • Figure 6-8: Global - Forecast for Rotavirus Vaccine Market Segmentation by Region (%), 2010
  • Figure 6-9: Global - Number of Diphtheria Incidences by Region, 2006
  • Figure 6-10: Global - Number of Pertussis Incidences by Region, 2006
  • Figure 6-11: Global - Number of nTetanus Incidences by Region, 2006
  • Figure 6-12: Global - Number of tTetanus Incidences by Region, 2006
  • Figure 6-13: Global - Share of DTP Combos Market by Player (%), 2004
  • Figure 6-14: Global - Number of Measles Incidences by Region, 2006
  • Figure 6-15: Global - Number of Mumps Incidences by Region, 2006
  • Figure 6-16: Global - Number of Rubella Incidences by Region, 2006
  • Figure 6-17: Global - Number of Tuberculosis Incidences (in Thousand), 2005
  • Figure 7-1: Global - Hepatitis B Surface Antigen Prevalence (%), 2005
  • Figure 7-2: Global - Hepatitis B Vaccine Market (in Million US$), 1999, 2005, 2006 & 2011F
  • Figure 8-1: Global - Profit Margins of Vaccines, Generics & Branded Drugs (%), 2007E
  • Figure 8-2: Global - Sources of Financing for Vaccine Market (%), 2001
  • Figure 8-3: Global - Prevnar Sales (in Million US$), 2003-2006
  • Figure 8-4: US - Drug Discovery Contract Research Organization Market (in Billion US$), 2006E & 2013E
  • Figure 8-5: Global - Dose Consumption & Revenue by Income of Region (%), 2005
  • Figure 9-1: Global - Share of Vaccine Market by Player (%), 2005
• List of Tables:
  • Table 5-1: China - Vaccines Classification
  • Table 5-2: China - Pediatric Vaccine Requirement (in Million Doses)
  • Table 5-3: Brazil - Public & Private Sectors Vaccine Market (in Million BRL), 2000
  • Table 7-1: Global - Number of HIV/AIDS Patients (in Million), 2006
  • Table 8-1: Global - Number of Deaths due to Diphtheria Averted by Vaccines (in Thousand), 2001
  • Table 8-2: Global - Cumulative Confirmed Human Cases & Number of Deaths due to Avian Influenza A/ (H5N1), 2003-2007
  • Table 9-1: Global - Share of Vaccines in Total Pharma Sales of Major Players (%), 2005
  • Table 9-2: Global - Growth of Vaccines Segment of Major Pharma Players (%), 2005
  • Table 9-3: Global - Overall Growth of Major Pharma Players (%), 2005
  • Table 9-4: Global - Major Vaccine Companies (Segmentation by Revenue)
  • Table 9-5: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
  • Table 9-6: GlaxoSmithKline Plc. - Key Financials (in Million US$), 2004-2006
  • Table 9-7: Merck & Co., Inc. - Key Financials (in Million US$), 2004-2006
  • Table 9-8: Novartis - Key Financials (in Million US$), 2004-2006
  • Table 9-9: Wyeth - Key Financials (in Million US$), 2004-2006